CDK4 and neoplasm: Incorporating our findings that PIK3CA mutation portends a worse prognosis even when tumor burden is low, patients should consider specific PIK3CA inhibitor in the earliest time after failure of standard first-line treatment of ET plus a CDK4/6 inhibitor.